These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 14735624)

  • 1. Blood supplies hit by vCJD fear.
    Strachan-Bennett S
    Nurs Times; 2004 Jan 6-12; 100(1):6. PubMed ID: 14735624
    [No Abstract]   [Full Text] [Related]  

  • 2. Japan plans blood-donor restrictions to combat vCJD.
    Fuyuno I
    Nature; 2005 Mar; 434(7031):260. PubMed ID: 15772611
    [No Abstract]   [Full Text] [Related]  

  • 3. Variant Creutzfeldt-Jakob disease and prions in the blood supply.
    Rohwer RG; Drohan W
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):84, 87, 131. PubMed ID: 16163166
    [No Abstract]   [Full Text] [Related]  

  • 4. Balancing evidence and public opinion in health technology assessments: the case of leukoreduction.
    Cleemput I; Leys M; Ramaekers D; Bonneux L
    Int J Technol Assess Health Care; 2006; 22(4):403-7. PubMed ID: 16984672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International views on universal leucodepletion: the perspective in NBS, England.
    Wallington T
    Transfus Sci; 1998 Dec; 19(4):347-8. PubMed ID: 10351150
    [No Abstract]   [Full Text] [Related]  

  • 6. ['Variant of Creutzfeldt-Jacob disease and blood transfusion'; report of the Dutch Health Council].
    van Aken WG
    Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1444-7. PubMed ID: 11503311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pressure grows over US blood ban.
    Goodman S
    Nature; 2001 Aug; 412(6846):467. PubMed ID: 11484010
    [No Abstract]   [Full Text] [Related]  

  • 8. Creutzfeldt-Jakob disease and blood products: FDA policy.
    Fratantoni JC
    Biologicals; 1998 Jun; 26(2):133-4. PubMed ID: 9811520
    [No Abstract]   [Full Text] [Related]  

  • 9. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products.
    Turner ML; Ludlam CA
    Br J Haematol; 2009 Jan; 144(1):14-23. PubMed ID: 18950452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three reported cases of variant Creutzfeldt-Jakob disease transmission following transfusion of labile blood components.
    Hewitt PE; Llewelyn CA; Mackenzie J; Will RG
    Vox Sang; 2006 Nov; 91(4):348. PubMed ID: 17105612
    [No Abstract]   [Full Text] [Related]  

  • 11. Recipients of blood or blood products "at vCJD risk".
    Bird SM
    BMJ; 2004 Jan; 328(7432):118-9. PubMed ID: 14726314
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of vCJD on blood supply.
    Seitz R; von Auer F; Blümel J; Burger R; Buschmann A; Dietz K; Heiden M; Hitzler WE; Klamm H; Kreil T; Kretzschmar H; Nübling M; Offergeld R; Pauli G; Schottstedt V; Volkers P; Zerr I
    Biologicals; 2007 Apr; 35(2):79-97. PubMed ID: 17320412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New variant CJD fears threaten blood supplies.
    Senior K
    Lancet; 2001 Jul; 358(9278):304. PubMed ID: 11498226
    [No Abstract]   [Full Text] [Related]  

  • 14. The application of the precautionary principle to the blood system: the Canadian blood system's vCJD donor deferral policy.
    Wilson K; Wilson M; Hébert PC; Graham I
    Transfus Med Rev; 2003 Apr; 17(2):89-94. PubMed ID: 12733102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Universal leucodepletion--practical and regulatory consequences.
    Barrowcliffe TW
    Transfus Sci; 1998 Dec; 19(4):361. PubMed ID: 10351156
    [No Abstract]   [Full Text] [Related]  

  • 16. Revised precautionary measures to reduce the possible transmission of Creutzfeldt-Jakob disease (CJD) by blood and blood products; guidance document; availability--FDA. Notice.
    Fed Regist; 1997 Sep; 62(184):49694-5. PubMed ID: 10173801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International views on universal leucodepletion: the perspective in Portugal.
    de Sousa G
    Transfus Sci; 1998 Dec; 19(4):351-2. PubMed ID: 10351152
    [No Abstract]   [Full Text] [Related]  

  • 18. The quandary of Creutzfeldt-Jakob disease.
    Larke B
    CMAJ; 1998 Oct; 159(7):789-92. PubMed ID: 9805025
    [No Abstract]   [Full Text] [Related]  

  • 19. International views on universal leucodepletion: the perspective in Germany.
    Seitz MD
    Transfus Sci; 1998 Dec; 19(4):359-60. PubMed ID: 10351155
    [No Abstract]   [Full Text] [Related]  

  • 20. The success of precaution? Managing the risk of transfusion transmission of variant Creutzfeldt-Jakob disease.
    Wilson K; Ricketts MN
    Transfusion; 2004 Oct; 44(10):1475-8. PubMed ID: 15383021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.